Allergan signage at the NYSE

Brendan McDermid | Reuters

AbbVie is close to a deal to buy Allergan for more than $60 billion, The Wall Street Journal reported Tuesday. An announcement is expected later in the day

The agreement is expected to be worth $188 a share in cash and stock, according to the report. At that price, it would represent a 45% premium above Allergan’s Monday closing price of $129.57.

Allergan’s shares soared more than 33% in premarket trading following the report. Shares of AbbVie were down more than 5%.

Read the complete Journal report here.

This story is developing. Please check back for updates.

Products You May Like

Articles You May Like

A new $400 million tech fund wants to help European tech compete with Silicon Valley and China
Jamie Dimon, who made $31 million last year, thinks wealth inequality is a problem
Everything Jim Cramer said on ‘Mad Money,’ including Cisco’s quarter, Viacom CEO, trade war divides
Elon Musk blames Brexit for decision to build new Tesla factory in Germany instead of UK
Homebuilder DR Horton sees 2020 home sales above estimates, shares rise

Leave a Reply

Your email address will not be published. Required fields are marked *